Loading…
Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit hyperactivity disorder - a placebo-controlled double-blind study
Objective : To investigate whether docosahexaenoic acid (DHA) supplementation was able to ameliorate attention-deficit/hyperactivity disorder(AD/HD) symptoms in AD/HD children. Design and subjects : A placebo-controlled double-blind study with 40 AD/HD (including eight AD/HD-suspected) children of 6...
Saved in:
Published in: | European journal of clinical nutrition 2004-03, Vol.58 (3), p.467-473 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objective
: To investigate whether docosahexaenoic acid (DHA) supplementation was able to ameliorate attention-deficit/hyperactivity disorder(AD/HD) symptoms in AD/HD children.
Design and subjects
: A placebo-controlled double-blind study with 40 AD/HD (including eight AD/HD-suspected) children of 6–12 y of age who were mostly without medication. Subjects of a DHA group (
n
=20) took active foods containing fish oil (fermented soybean milk, bread rolls and steamed bread; 3.6 g DHA/week from these foods) for 2 months, whereas those of a control group (
n
=20) took indistinguishable control foods without fish oil. The following items were measured at the start and end of the study: (1) attention deficit, hyperactivity and impulsivity (AD/HD-related symptoms according to DSM-IV criteria); (2) aggression assessed by both parents and teachers; (3) visual perception (finding symbols out of a table); (4) visual and auditory short-term memory; (5) development of visual–motor integration; (6) continuous performance; (7) impatience.
Results
: Changes in tests 1, 2, 3, 5 and 7 over time did not significantly differ between the two groups. However, visual short-term memory and errors of commission (continuous performance) significantly improved in the control group compared with the changes over time in the DHA group (
P
=0.02 and 0.001, respectively). Recalculation without AD/HD-suspected subjects (
n
=4 each group) showed similar
P
-values with regard to both measures.
Conclusions
: DHA supplementation did not improve AD/HD-related symptoms. Treatment of ADHD with fatty acids deserves further investigation, but careful attention should be paid as to which fatty acid(s) is used. |
---|---|
ISSN: | 0954-3007 1476-5640 |
DOI: | 10.1038/sj.ejcn.1601830 |